SMART trial finds Medtronic's Evolut TAVR platform non-inferior for small aortic annuli patients with superior valve performance compared to Edwards Lifesciences' Sapien device.
The SMART trial, the largest head-to-head comparative TAVR study, shows that Medtronic's Evolut TAVR platform provides non-inferior clinical outcomes and superior valve performance compared to Edwards Lifesciences' Sapien device in patients with small aortic annuli, primarily women. The one-year data demonstrates that the Evolut TAVR system is an optimal treatment option for severe aortic stenosis patients with small annulus.
April 07, 2024
7 Articles